Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Option and Sells Shares Under 10b5-1 Plan

Enliven Therapeutics' CEO, Samuel Kintz, exercised stock options and sold 12,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 25, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, exercised options to purchase 12,000 shares of common stock at a price of $1.12 per share.
• Simultaneously, Kintz sold 12,000 shares of common stock at a weighted average price of $16.8917 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following these transactions, Kintz directly owns no shares of common stock.
• Kintz indirectly owns 1,087,525 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
• He also indirectly owns 88,531 shares through an irrevocable trust dated October 26, 2021, for the benefit of his elder son, and another 88,531 shares through a similar trust for his younger son, acting as investment advisor for both.
• After the transaction, Kintz directly owns 200,841 stock options.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions under a pre-arranged trading plan. While insider sales can sometimes raise concerns, the existence of the 10b5-1 plan mitigates this.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• While the 10b5-1 plan mitigates some concerns, significant insider selling could still create negative market sentiment.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common and closely watched in the biotech industry. Investors often analyze these filings to gauge management's confidence in the company's prospects. Rule 10b5-1 plans are frequently used to schedule transactions and avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Comparing the CEO's trading activity to peers like Pfizer, Johnson & Johnson, or Amgen is difficult without knowing the specific details of their compensation packages and trading plans.
• However, it's common for executives in publicly traded companies to have pre-arranged trading plans to manage their stock holdings.
• The size of the transaction (12,000 shares) is relatively small compared to the total outstanding shares, suggesting it's unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on their interpretation of the CEO's stock sales.
• Employees may also be interested in insider trading activity as an indicator of company health.

Key Dates